Arcus Biosciences - Stock Split History | RCUS

Stock split history for Arcus Biosciences since 2022. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Arcus Biosciences Annual Stock Splits
Arcus Biosciences Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.888B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.795B 9.21
GSK (GSK) United Kingdom $59.851B 7.19
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.831B 0.00
QIAGEN (QGEN) Netherlands $9.374B 15.70
Ginkgo Bioworks Holdings (DNA) United States $5.569B 0.00
Myovant Sciences (MYOV) United Kingdom $1.723B 0.00
Emergent Biosolutions (EBS) United States $1.047B 6.07
ADC Therapeutics SA (ADCT) Switzerland $0.370B 0.00
Zymeworks (ZYME) Canada $0.356B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
Gelesis Holdings (GLS) United States $0.078B 0.00
SQZ Biotechnologies (SQZ) United States $0.067B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00